BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997;25:87-92. [PMID: 8985270 DOI: 10.1002/hep.510250116] [Cited by in Crossref: 264] [Cited by in F6Publishing: 181] [Article Influence: 10.6] [Reference Citation Analysis]
Number Citing Articles
1 Qu L, Liu J, Zhu J, Lu C. Risk Factors for Prognosis of Hepatocellular Carcinoma After Curative Resection In Patients with Low Hepatitis B Viral Load. Annals of Hepatology 2017;16:412-20. [DOI: 10.5604/01.3001.0009.8596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
2 Shimada M, Yamashita Y, Hamatsu T, Hasegawa H, Utsunomiya T, Aishima S, Sugimachi K. The role of des-gamma-carboxy prothrombin levels in hepatocellular carcinoma and liver tissues. Cancer Lett. 2000;159:87-94. [PMID: 10974410 DOI: 10.1016/s0304-3835(00)00539-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Trinchet J, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. Journal of Hepatology 1997;27:756-65. [DOI: 10.1016/s0168-8278(97)80095-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
4 Minata M, Nishida N, Komeda T, Azechi H, Katsuma H, Nishimura T, Kuno M, Ito T, Yamamoto Y, Ikai I. Postoperative detection of alpha-fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16:445-451. [PMID: 11354284 DOI: 10.1046/j.1440-1746.2001.02461.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.1] [Reference Citation Analysis]
5 Li QG, Yang GS, Yang Q, Wei LX, Yang N, Zhou XP, Jia FQ. Disseminated tumor cells homing into rats’ liver: A new possible mechanism of HCC recurrence. World J Gastroenterol 2004; 10(6): 903-905 [PMID: 15040042 DOI: 10.3748/wjg.v10.i6.903] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
6 Ahn S, Hyeon J, Park CK. Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12:286-294. [PMID: 23742774 DOI: 10.1016/s1499-3872(13)60046-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
7 Yamashiki N, Yoshida H, Tateishi R, Shiina S, Teratani T, Yoshida H, Kondo Y, Oki T, Kawabe T, Omata M. Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment. J Gastroenterol Hepatol 2007;22:2155-60. [DOI: 10.1111/j.1440-1746.2006.04732.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
8 Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856-1864. [PMID: 15779015 DOI: 10.1002/cncr.20976] [Cited by in Crossref: 176] [Cited by in F6Publishing: 176] [Article Influence: 10.4] [Reference Citation Analysis]
9 Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma: Evidence-based treatment of HCC. Journal of Gastroenterology and Hepatology 2002;17:S428-33. [DOI: 10.1046/j.1440-1746.17.s3.40.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
10 Alsinet C, Villanueva A. [Genomic prognostic markers in hepatocellular carcinoma]. Gastroenterol Hepatol 2012;35:94-101. [PMID: 22178501 DOI: 10.1016/j.gastrohep.2011.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Zhang L, Qin L, Ma Z, Ye S, Liu Y, Ye Q, Wu X, Huang W, Tang Z. Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis. J Cancer Res Clin Oncol 2003;129:279-86. [DOI: 10.1007/s00432-002-0407-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
12 Nghiem HV, Francis IR, Fontana R, Hussain H, Platt JF, Higgins E, Bree RL. Computed tomography appearances of hypervascular hepatic tumors after percutaneous radiofrequency ablation therapy. Current Problems in Diagnostic Radiology 2002;31:105-11. [DOI: 10.1067/cdr.2002.125400] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
13 Zhai XF, Chen Z, Li B, Shen F, Fan J, Zhou WP, Yang YK, Xu J, Qin X, Li LQ. Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. J Integr Med. 2013;11:90-100. [PMID: 23506690 DOI: 10.3736/jintegrmed2013021] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 6.7] [Reference Citation Analysis]
14 Imura S, Tovuu LO, Utsunomiya T, Morine Y, Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Takasu C, Yamada S, Ishikawa D, Bando Y, Shimada M. Role of Fbxw7 expression in hepatocellular carcinoma and adjacent non-tumor liver tissue. J Gastroenterol Hepatol 2014;29:1822-9. [PMID: 24731221 DOI: 10.1111/jgh.12623] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
15 Kim do Y, Ahn SH, Kim SU, Choi SB, Lee KH, Park MS, Park JY, Lee do Y, Han KH, Kim KS. Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. Oncology. 2011;81:184-191. [PMID: 22067673 DOI: 10.1159/000333827] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
16 Shimizu M, Takai K, Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 2009;100:369-74. [PMID: 19068086 DOI: 10.1111/j.1349-7006.2008.01045.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
17 Yano M, Hamatani K, Eguchi H, Hirai Y, MacPhee DG, Sugino K, Dohi K, Itamoto T, Asahara T. Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes. Eur J Cancer 2007;43:1092-100. [PMID: 17350822 DOI: 10.1016/j.ejca.2007.01.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
18 Ueki T, Sakaguchi S, Miyajima Y, Hatono N, Tohara K, Nakabayashi S, Yao T, Kokawa H, Hirano M, Okumura M. Usefulness of tumor pressure as a prognostic factor in cases of hepatocellular carcinoma where the diameter of the tumor is 3 cm or less. Cancer 2002;95:596-604. [PMID: 12209753 DOI: 10.1002/cncr.10690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
19 Du ZG, Wei YG, Chen KF, Li B. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients. Hepatobiliary Pancreat Dis Int 2014;13:153-61. [PMID: 24686542 DOI: 10.1016/s1499-3872(14)60025-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
20 Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1929-1935. [PMID: 17914972 DOI: 10.1111/j.1440-1746.2006.04707.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
21 Kawamoto C, Ido K, Isoda N, Hozumi M, Nagamine N, Ono K, Sato Y, Kobayashi Y, Nagae G, Sugano K. Long-term outcomes for patients with solitary hepatocellular carcinoma treated by laparoscopic microwave coagulation. Cancer. 2005;103:985-993. [PMID: 15672389 DOI: 10.1002/cncr.20880] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
22 An HJ, Jang JW, Bae SH, Choi JY, Cho SH, Yoon SK, Han JY, Lee KH, Kim DG, Jung ES. Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1876-1882. [PMID: 21092000 DOI: 10.1111/j.1440-1746.2010.06416.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
23 Schiffman SC, Woodall CE, Kooby DA, Martin RC, Staley CA, Egnatashvili V, McMasters KM, Scoggins CR. Factors associated with recurrence and survival following hepatectomy for large hepatocellular carcinoma: a multicenter analysis. J Surg Oncol. 2010;101:105-110. [PMID: 20035538 DOI: 10.1002/jso.21461] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
24 Minata M, Kudo M, Harada KH, Ikai I, Nishida N. Expression of E-cadherin and vascular endothelial growth factor in noncancerous liver is associated with recurrence of hepatocellular carcinoma after curative resection. Oncology. 2013;84 Suppl 1:88-92. [PMID: 23428865 DOI: 10.1159/000345896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
25 Takaki H, Yamakado K, Sakurai H, Nakatsuka A, Shiraki K, Isaji S, Takeda K. Radiofrequency Ablation Combined With Chemoembolization: Treatment of Recurrent Hepatocellular Carcinomas After Hepatectomy. American Journal of Roentgenology 2011;197:488-94. [DOI: 10.2214/ajr.10.4933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Shimada K, Sakamoto Y, Esaki M, Kosuge T. Role of the width of the surgical margin in a hepatectomy for small hepatocellular carcinomas eligible for percutaneous local ablative therapy. The American Journal of Surgery 2008;195:775-81. [DOI: 10.1016/j.amjsurg.2007.06.033] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
27 Kobayashi A, Miyagawa S, Miwa S, Nakata T. Prognostic impact of anatomical resection on early and late intrahepatic recurrence in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2008;15:515-21. [PMID: 18836806 DOI: 10.1007/s00534-007-1293-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
28 Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013;35:111-20. [DOI: 10.1007/s00281-012-0330-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
29 Seki T, Wakabayashi M, Nakagawa T, Imamura M, Tamai T, Nishimura A, Yamashiki N, Okamura A, Inoue K. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: Comparison with percutaneous ethanol injection therapy. Cancer 1999;85:1694-702. [DOI: 10.1002/(sici)1097-0142(19990415)85:8<1694::aid-cncr8>3.0.co;2-3] [Cited by in Crossref: 151] [Cited by in F6Publishing: 1] [Article Influence: 6.6] [Reference Citation Analysis]
30 Khan KN, Yatsuhashi H, Yamasaki K, Yamasaki M, Inoue O, Koga M, Yano M. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol. 2000;32:269-278. [PMID: 10707867 DOI: 10.1016/s0168-8278(00)80072-0] [Cited by in Crossref: 106] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
31 Tanaka S, Iimuro Y, Hirano T, Hai S, Suzumura K, Fujimoto J. Outcomes of Hepatic Resection for Large Hepatocellular Carcinoma: Special Reference to Postoperative Recurrence. The American Surgeon 2015;81:64-73. [DOI: 10.1177/000313481508100132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Bigourdan JM, Jaeck D, Meyer N, Meyer C, Oussoultzoglou E, Bachellier P, Weber JC, Audet M, Doffoël M, Wolf P. Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. Liver Transpl. 2003;9:513-520. [PMID: 12740796 DOI: 10.1053/jlts.2003.50070] [Cited by in Crossref: 126] [Cited by in F6Publishing: 124] [Article Influence: 6.6] [Reference Citation Analysis]
33 Shindoh J, Hasegawa K, Matsuyama Y, Inoue Y, Ishizawa T, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. J Clin Oncol. 2013;31:766-773. [PMID: 23129744 DOI: 10.1200/jco.2012.44.3234] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
34 Tajima T, Yoshimitsu K, Irie H, Aibe H, Shinozaki K, Nishie A, Honda H, Shimada M. Detecting Postsurgical Recurrent Hepatocellular Carcinoma With Multiphasic Helical Computed Tomography: Intrahepatic Metastasis or Multicentric Occurrence? Journal of Computer Assisted Tomography 2005;29:42-50. [DOI: 10.1097/01.rct.0000146482.64324.6e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
35 Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, Gotoh K, Yamada T, Tomita Y. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol. 2009;44:1190-1194. [PMID: 19672551 DOI: 10.1007/s00535-009-0112-0] [Cited by in Crossref: 144] [Cited by in F6Publishing: 141] [Article Influence: 12.0] [Reference Citation Analysis]
36 Kanamori T, Shimizu M, Okuno M, Matsushima-nishiwaki R, Tsurumi H, Kojima S, Moriwaki H. Synergistic growth inhibition by acyclic retinoid and vitamin K 2 in human hepatocellular carcinoma cells. Cancer Science 2007;98:431-7. [DOI: 10.1111/j.1349-7006.2006.00384.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
37 Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, Villani MR, Cedrone A, Gasbarrini G. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 2001;92:126-35. [DOI: 10.1002/1097-0142(20010701)92:1<126::aid-cncr1300>3.0.co;2-v] [Cited by in Crossref: 59] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
38 Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, Lee KU, Chung JW, Park JH, Kim CY. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol. 2002;20:4459-4465. [PMID: 12431969 DOI: 10.1200/jco.2002.02.013] [Cited by in Crossref: 86] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
39 Shimizu M, Shirakami Y, Hanai T, Imai K, Suetsugu A, Takai K, Shiraki M, Moriwaki H. Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids. Mol Nutr Food Res 2014;58:124-35. [PMID: 24273224 DOI: 10.1002/mnfr.201300538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
40 Liu QY, Lai DM, Liu C, Zhang L, Zhang WD, Li HG, Gao M. A special recurrent pattern in small hepatocellular carcinoma after treatment: Bile duct tumor thrombus formation. World J Gastroenterol 2011; 17(43): 4817-4824 [PMID: 22147984 DOI: 10.3748/wjg.v17.i43.4817] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
41 Kaibori M, Kon M, Kitawaki T, Kawaura T, Hasegawa K, Kokudo N, Ariizumi S, Beppu T, Ishizu H, Kubo S, Kamiyama T, Takamura H, Kobayashi T, Kim DS, Wang HJ, Kim JM, Han DH, Park SJ, Kang KJ, Hwang S, Roh Y, You YK, Joh JW, Yamamoto M. Comparison of anatomic and non-anatomic hepatic resection for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2017;24:616-26. [PMID: 28887834 DOI: 10.1002/jhbp.502] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
42 Hosaka T, Ikeda K, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki F, Suzuki Y. Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma. Liver Int. 2009;29:736-742. [PMID: 19018978 DOI: 10.1111/j.1478-3231.2008.01901.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
43 Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, Kosuge T, Okada S, Takayasu K, Yamasaki S. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998;28:1241-1246. [PMID: 9794907 DOI: 10.1002/hep.510280511] [Cited by in Crossref: 294] [Cited by in F6Publishing: 262] [Article Influence: 12.3] [Reference Citation Analysis]
44 Tsujiuchi T, Sugata E, Masaoka T, Onishi M, Fujii H, Shimizu K, Honoki K. Expression and DNA methylation patterns of Tslc1 and Dal-1 genes in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Cancer Sci 2007;98:943-8. [PMID: 17428255 DOI: 10.1111/j.1349-7006.2007.00480.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
45 Shimada K, Sano T, Sakamoto Y, Kosuge T. A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer. 2005;104:1939-1947. [PMID: 16177997 DOI: 10.1002/cncr.21461] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 3.9] [Reference Citation Analysis]
46 Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y. Platelet–lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. European Journal of Gastroenterology & Hepatology 2021;32:261-8. [DOI: 10.1097/meg.0000000000001734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
47 Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, Asahara T, Kajiyama G. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrocholoride emulsion. J Vasc Intervent Radiol. 2001;12:847-854. [PMID: 11435541 DOI: 10.1016/s1051-0443(07)61510-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
48 Yamamoto M, Takasaki K, Ohtsubo T, Katsuragawa H, Fukuda C, Katagiri S. Effectiveness of systematized hepatectomy with Glisson's pedicle transection at the hepatic hilus for small nodular hepatocellular carcinoma: retrospective analysis. Surgery 2001;130:443-8. [PMID: 11562668 DOI: 10.1067/msy.2001.116406] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 4.4] [Reference Citation Analysis]
49 Hoshida Y, Shiratori Y, Omata M. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma: Interferon after resection of HCC. Liver 2002;22:479-85. [DOI: 10.1034/j.1600-0676.2002.01736.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
50 Zhang X, Li C, Wen T, Peng W, Yan L, Yang J. Treatment for intrahepatic recurrence after curative resection of hepatocellular carcinoma: Salvage liver transplantation or re-resection/radiofrequency ablation? A Retrospective Cohort Study. Int J Surg 2017;46:178-85. [PMID: 28890407 DOI: 10.1016/j.ijsu.2017.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
51 Yokoyama K, Anan A, Iwata K, Nishizawa S, Morihara D, Ueda S, Sakurai K, Iwashita H, Hirano G, Sakamoto M. Limitation of repeated radiofrequency ablation in hepatocellular carcinoma: proposal of a three (times) × 3 (years) index. J Gastroenterol Hepatol. 2012;27:1044-1050. [PMID: 22433056 DOI: 10.1111/j.1440-1746.2012.07134.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
52 Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, Li H, Hao X. Clonality Analysis for Multicentric Origin and Intrahepatic Metastasis in Recurrent and Primary Hepatocellular Carcinoma. J Gastrointest Surg 2008;12:1540-7. [DOI: 10.1007/s11605-008-0591-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
53 Sasaki K, Shindoh J, Nishioka Y, Margonis GA, Sugawara T, Andreatos N, Hashimoto M, Pawlik TM. Impact of Viral Etiology on Postoperative De Novo Recurrence After Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Patients. J Gastrointest Surg 2017;21:487-95. [DOI: 10.1007/s11605-016-3344-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
54 Olesinski J, Mithieux F, Guillaud O, Hilleret MN, Lombard-Bohas C, Henry L, Boillot O, Walter T, Partensky C, Paliard P, Valette PJ, Vuillez JP, Borson-Chazot F, Scoazec JY, Dumortier J. Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years. Ann Nucl Med 2017;31:379-89. [PMID: 28342103 DOI: 10.1007/s12149-017-1165-4] [Reference Citation Analysis]
55 Merle P, Barraud L, Lefrançois L, Chevallier M, Guerret S, Maisonnas M, Bordes I, Savre-Train I, Trepo C, Vitvitski-Trepo L. Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice. Oncogene 2003;22:2762-71. [PMID: 12743599 DOI: 10.1038/sj.onc.1206375] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
56 Hayashi K, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Miyata A, Shimizu H, Satomura S. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999;94:3028-33. [PMID: 10520864 DOI: 10.1111/j.1572-0241.1999.01378.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 46] [Article Influence: 1.4] [Reference Citation Analysis]
57 Tanaka S, Tamori A, Takemura S, Hamano G, Ito T, Kawada N, Kubo S. Surgical Outcomes in Hepatitis C Virus-Related Hepatocellular Carcinoma: Special Reference to Sustained Virological Responses to Interferon Therapy. The American Surgeon 2017;83:1246-55. [DOI: 10.1177/000313481708301127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
58 Inoue K, Takayama T, Higaki T, Watanabe Y, Makuuchi M. Clinical significance of early hepatocellular carcinoma. Liver Transpl 2004;10:S16-9. [DOI: 10.1002/lt.20049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
59 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37. [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022] [Cited by in Crossref: 576] [Cited by in F6Publishing: 571] [Article Influence: 41.1] [Reference Citation Analysis]
60 Tomimaru Y, Nagano H, Eguchi H, Kobayashi S, Marubashi S, Wada H, Tanemura M, Umeshita K, Hiramatsu N, Takehara T, Doki Y, Mori M. Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2010;102:308-14. [DOI: 10.1002/jso.21633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
61 Yang B, Gao YT, Du Z, Zhao L, Song WQ. Methylation-based molecular margin analysis in hepatocellular carcinoma. Biochem Biophys Res Commun. 2005;338:1353-1358. [PMID: 16269133 DOI: 10.1016/j.bbrc.2005.10.095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
62 Kanogawa N, Ogasawara S, Chiba T, Saito T, Motoyama T, Suzuki E, Ooka Y, Tawada A, Kanda T, Mikami S. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol. 2015;30:1197-1204. [PMID: 25682720 DOI: 10.1111/jgh.12925] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
63 Yamamoto J, Kosuge T, Saiura A, Sakamoto Y, Shimada K, Sano T, Takayama T, Sugawara Y, Yamaguchi T, Kokudo N, Makuuchi M. Effectiveness of Hepatic Resection for Early-stage Hepatocellular Carcinoma in Cirrhotic Patients: Subgroup Analysis according to Milan Criteria. Japanese Journal of Clinical Oncology 2007;37:287-95. [DOI: 10.1093/jjco/hym025] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
64 Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Shibata K, Ohta M, Kitano S. Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol. 2009;35:174-179. [PMID: 18325724 DOI: 10.1016/j.ejso.2008.01.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
65 Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, Kodai S, Shinkawa H, Shuto T, Hirohashi K. Surgical Treatment for Hepatocellular Carcinoma Detected After Successful Interferon Therapy. Surg Today 2007;37:285-90. [DOI: 10.1007/s00595-006-3403-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
66 Kairemo KJ, Vehmas T, Bondestam S. A Novel Method for Monitoring Liver Ethanol Injections. Alcohol 1999;19:145-9. [DOI: 10.1016/s0741-8329(99)00031-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
67 Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Hisanaga Y. Characteristics and course of small hepatocellular carcinomas in patients with hepatitis C virus types 1 and 2. J Med Virol 2001;63:120-7. [DOI: 10.1002/1096-9071(20000201)63:2<120::aid-jmv1006>3.0.co;2-2] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
68 Marrero JA, Welling T. Modern Diagnosis and Management of Hepatocellular Carcinoma. Clinics in Liver Disease 2009;13:233-47. [DOI: 10.1016/j.cld.2009.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
69 Hu C, Wu J, Cheng C, Wang S, Wang H, Lee M, Wang L, Pan S, Chang T, Wu W. Reactive oxygen species-mediated PKC and integrin signaling promotes tumor progression of human hepatoma HepG2. Clin Exp Metastasis 2011;28:851-63. [DOI: 10.1007/s10585-011-9416-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
70 Bartolozzi C, Cioni D, Donati F, Granai G, Lencioni R. Imaging Evaluation of Tumor Response. In: Bartolozzi C, Lencioni R, editors. Liver Malignancies. Berlin: Springer Berlin Heidelberg; 1999. pp. 467-87. [DOI: 10.1007/978-3-642-58641-5_30] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
71 Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Effects of a 24-week course of interferon-α therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007; 13(40): 5343-5350 [PMID: 17879404 DOI: 10.3748/wjg.v13.i40.5343] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
72 Horigome H, Nomura T, Saso K, Itoh M. Standards for selecting percutaneous ethanol injection therapy or percutaneous microwave coagulation therapy for solitary small hepatocellular carcinoma: consideration of local recurrence. Am J Gastroenterol. 1999;94:1914-1917. [PMID: 10406259 DOI: 10.1111/j.1572-0241.1999.01230.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
73 Fukutomi S, Nomura Y, Nakashima O, Yano H, Tanaka H, Akagi Y, Okuda K. Evaluation of hepatocellular carcinoma spread via the portal system by 3-dimensional mapping. HPB (Oxford) 2017;19:1119-25. [PMID: 28888777 DOI: 10.1016/j.hpb.2017.08.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
74 Huang GQ, Xie YY, Zhu PW, Wang XD, Lin Z, Wang Y, Ye JP, Wang YM, Chen YX, Jin XZ, Van Poucke S, Chen YP, Zheng MH. Stratified alpha-fetoprotein pattern accurately predicts mortality in patients with acute-on-chronic hepatitis B liver failure. Expert Rev Gastroenterol Hepatol 2018;12:295-302. [PMID: 29300103 DOI: 10.1080/17474124.2018.1424540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma. J Hepatol. 2006;45:868-878. [PMID: 17046096 DOI: 10.1016/j.jhep.2006.09.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
76 Shimada M, Hasegawa H, Gion T, Utsunomiya T, Shirabe K, Takenaka K, Otsuka T, Maehara Y, Sugimachi K. The role of telomerase activity in hepatocellular carcinoma. Am J Gastroenterol. 2000;95:748-752. [PMID: 10710069 DOI: 10.1111/j.1572-0241.2000.01855.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
77 Oh SH, Lee BH. A ginseng saponin metabolite-induced apoptosis in HepG2 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and Bid cleavage. Toxicol Appl Pharmacol. 2004;194:221-229. [PMID: 14761678 DOI: 10.1016/j.taap.2003.09.011] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
78 Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Nakamura N, Ito K, Miki Y, Inazawa J, Tanaka H, Arii S. Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas. Surgery 2010;147:405-14. [DOI: 10.1016/j.surg.2009.09.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
79 Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Yamamoto T, Ikebe T, Wakasa K, Nishiguchi S, Kinoshita H. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000;88:1016-24. [DOI: 10.1002/(sici)1097-0142(20000301)88:5<1016::aid-cncr10>3.0.co;2-v] [Cited by in Crossref: 75] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
80 Marubashi S, Nagano H, Wada H, Kobayashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Clinical significance of alpha-fetoprotein mRNA in peripheral blood in liver resection for hepatocellular carcinoma. Ann Surg Oncol 2011;18:2200-9. [PMID: 21301972 DOI: 10.1245/s10434-011-1577-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
81 Mela M, Mancuso A, Burroughs AK. Review article: hepatocellular carcinoma: indications for liver transplantation. Aliment Pharmacol Ther. 2003;17 Suppl 2:130-137. [PMID: 12786624 DOI: 10.1046/j.1365-2036.17.s2.16.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
82 Lee CH, Brubaker LM, Gerber DA, Ku YM, Kim YH, Shin SS, Semelka RC. MRI findings of recurrent hepatocellular carcinoma after liver transplantation: preliminary results. J Magn Reson Imaging. 2011;33:1399-1405. [PMID: 21591009 DOI: 10.1002/jmri.22326] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
83 Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M. α-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: A prospective study: α-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: A prospective study. Hepatology 2002;35:853-60. [DOI: 10.1053/jhep.2002.32100] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 3.5] [Reference Citation Analysis]
84 Yoshioka S, Takemasa I, Nagano H, Kittaka N, Noda T, Wada H, Kobayashi S, Marubashi S, Takeda Y, Umeshita K. Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer. 2009;45:881-889. [PMID: 19167881 DOI: 10.1016/j.ejca.2008.12.019] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
85 Dong B, Liang P, Yu X, Su L, Yu D, Cheng Z, Zhang J. Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients. AJR Am J Roentgenol. 2003;180:1547-1555. [PMID: 12760916 DOI: 10.2214/ajr.180.6.1801547] [Cited by in Crossref: 165] [Cited by in F6Publishing: 137] [Article Influence: 8.7] [Reference Citation Analysis]
86 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Uesaka K. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:4566-75. [PMID: 31602577 DOI: 10.1245/s10434-019-07911-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
87 Wang S, Chuang S, Lee K. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study: Sorafenib prevents early HCC recurrence. Hepatol Res 2014;44:523-31. [DOI: 10.1111/hepr.12159] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
88 Tada T, Kumada T, Toyoda H, Ito T, Sone Y, Kaneoka Y, Maeda A, Okuda S, Otobe K, Takahashi K. Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma. Ultrasound in Medicine & Biology 2015;41:3070-8. [DOI: 10.1016/j.ultrasmedbio.2015.07.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
89 Ha SY, Kim JH, Yang JW, Bae H, Cho HY, Park C. Expression of DBC1 is associated with poor prognosis in hepatitis virus-related hepatocellular carcinoma. Pathology - Research and Practice 2016;212:616-21. [DOI: 10.1016/j.prp.2016.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
90 Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Sone Y, Kaneoka Y, Maeda A. Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. J Hepatol. 2013;58:1174-1180. [PMID: 23376360 DOI: 10.1016/j.jhep.2013.01.030] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
91 Fukui K, Tamura S, Wada A, Kamada Y, Sawai Y, Imanaka K, Kudara T, Shimomura I, Hayashi N. Expression and prognostic role of RhoA GTPases in hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:627-33. [DOI: 10.1007/s00432-006-0107-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
92 Cui X, Wu Y, Wang Z, Liu X, Wang S, Qin C. MicroRNA-34a expression is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. Tumour Biol. 2015;36:3887-3893. [PMID: 25596083 DOI: 10.1007/s13277-014-3031-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
93 Tanaka Y, Kanai F, Tada M, Tateishi R, Sanada M, Nannya Y, Ohta M, Asaoka Y, Seto M, Shiina S, Yoshida H, Kawabe T, Yokosuka O, Ogawa S, Omata M. Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma. J Hepatol. 2008;49:746-757. [PMID: 18752864 DOI: 10.1016/j.jhep.2008.06.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
94 Santambrogio R, Opocher E, Costa M, Cappellani A, Montorsi M. Survival and intra-hepatic recurrences after laparoscopic radiofrequency of hepatocellular carcinoma in patients with liver cirrhosis. J Surg Oncol. 2005;89:218-225; discussion 225-226. [PMID: 15726623 DOI: 10.1002/jso.20204] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
95 Ryu SH, Jang MK, Kim WJ, Lee D, Chung YH. Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine. Cancer Metastasis Rev 2014;33:965-80. [PMID: 25325987 DOI: 10.1007/s10555-014-9522-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
96 Osada S, Saji S, Kuno T. Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. J Surg Oncol 2004;85:48-54. [DOI: 10.1002/jso.20006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
97 Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2008;98:358-62. [PMID: 18646001 DOI: 10.1002/jso.21111] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
98 Feng YX, Wang T, Deng YZ, Yang P, Li JJ, Guan DX, Yao F, Zhu YQ, Qin Y, Wang H. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology. 2011;53:483-492. [PMID: 21274870 DOI: 10.1002/hep.24075] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
99 Gournay J, Tchuenbou J, Richou C, Masliah C, Lerat F, Dupas B, Martin T, Nouel JF, Schnée M, Montigny P, D'alincourt A, Hamy A, Paineau J, Le Néel J-, Le Borgne J, Galmiche JP. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis: PERCUTANEOUS ETHANOL INJECTION VS. RESECTION IN HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2002;16:1529-38. [DOI: 10.1046/j.1365-2036.2002.01307.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
100 Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Hamamura K, Imai Y, Yoshida H, Shiina S. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology. 2000;32:1216-1223. [PMID: 11093727 DOI: 10.1053/jhep.2000.20237] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 4.5] [Reference Citation Analysis]
101 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
102 Kubo S. Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy. Clin J Gastroenterol 2009;2:65-70. [DOI: 10.1007/s12328-009-0072-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
103 Wang J, Lu S, Tung H, Changchien C, Hung C, Chen C, Lee, C. Flash-echo contrast sonography in the evaluation of response of small hepatocellular carcinoma to percutaneous ablation. J Clin Ultrasound 2006;34:161-8. [DOI: 10.1002/jcu.20217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
104 Zhang X, Meng B, Qi X, Yu L, Liu C, Liu X, Wang B, Pan C, Lv Y. Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: The surgeon's role in survival. European Journal of Surgical Oncology (EJSO) 2009;35:622-8. [DOI: 10.1016/j.ejso.2008.08.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
105 Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma: PEGIFN/RBV after treatment for HCC. Journal of Viral Hepatitis 2011;18:e550-60. [DOI: 10.1111/j.1365-2893.2011.01468.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
106 Sun H, Tang Z, Ma Z, Qin L, Wang L, Ye Q, Fan J, Wu Z, Zhou X. The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background. J Cancer Res Clin Oncol 2005;131:284-8. [DOI: 10.1007/s00432-004-0645-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
107 Adachi E, Maehara S, Tsujita E, Taguchi K, Aishima S, Rikimaru T, Yamashita Y, Tanaka S. Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma. Surgery. 2002;131:S148-S152. [PMID: 11821802 DOI: 10.1067/msy.2002.119496] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
108 Hui AM, Takayama T, Sano K, Kubota K, Akahane M, Ohtomo K, Makuuchi M. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol 2000;33:975-9. [PMID: 11131461 DOI: 10.1016/s0168-8278(00)80131-2] [Cited by in Crossref: 82] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
109 Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006; 12(45): 7239-7249 [PMID: 17143937 DOI: 10.3748/wjg.v12.i45.7239] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
110 Faber W, Stockmann M, Schirmer C, Möllerarnd A, Denecke T, Bahra M, Klein F, Schott E, Neuhaus P, Seehofer D. Significant impact of patient age on outcome after liver resection for HCC in cirrhosis. Eur J Surg Oncol. 2014;40:208-213. [PMID: 24275202 DOI: 10.1016/j.ejso.2013.10.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
111 Matsuda M, Ichikawa S, Matsuda M, Amemiya H, Ichikawa D, Onishi H, Motosugi U. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement as a risk factor for late recurrence (>1 year) of hepatocellular carcinoma after surgery. Clin Radiol 2019;74:975.e1-9. [PMID: 31540704 DOI: 10.1016/j.crad.2019.08.002] [Reference Citation Analysis]
112 Obora A, Shiratori Y, Okuno M, Adachi S, Takano Y, Matsushima-Nishiwaki R, Yasuda I, Yamada Y, Akita K, Sano T. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology. 2002;36:1115-1124. [PMID: 12395321 DOI: 10.1053/jhep.2002.36369] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
113 Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Kaneoka Y, Maeda A. Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol. 2012;57:1251-1257. [PMID: 22824818 DOI: 10.1016/j.jhep.2012.07.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
114 Rou WS, Lee BS, Moon HS, Lee ES, Kim SH, Lee HY. Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol 2014; 20(22): 6995-7004 [PMID: 24944494 DOI: 10.3748/wjg.v20.i22.6995] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
115 Shinkawa H, Tanaka S, Takemura S, Amano R, Kimura K, Kinoshita M, Takahashi K, Matsuzaki S, Kubo S. Nomograms predicting extra- and early intrahepatic recurrence after hepatic resection of hepatocellular carcinoma. Surgery 2021;169:922-8. [PMID: 33190917 DOI: 10.1016/j.surg.2020.10.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
116 Kondo K, Chijiiwa K, Makino I, Kai M, Maehara N, Ohuchida J, Naganuma S. Risk factors for early death after liver resection in patients with solitary hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2005;12:399-404. [PMID: 16258809 DOI: 10.1007/s00534-005-1009-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
117 Chan AC, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, Fan ST, Lo CM. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl. 2013;19:411-419. [PMID: 23447460 DOI: 10.1002/lt.23605] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 7.8] [Reference Citation Analysis]
118 Peng ZW, Lin XJ, Zhang YJ, Liang HH, Guo RP, Shi M, Chen MS. Radiofrequency ablation vs hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology. 2012;262:1022-1033. [PMID: 22357902 DOI: 10.1148/radiol.11110817] [Cited by in Crossref: 141] [Cited by in F6Publishing: 130] [Article Influence: 14.1] [Reference Citation Analysis]
119 Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome-oriented decision analysis. Hepatology. 2000;31:899-906. [PMID: 10733546 DOI: 10.1053/he.2000.5763] [Cited by in Crossref: 234] [Cited by in F6Publishing: 228] [Article Influence: 10.6] [Reference Citation Analysis]
120 Hagihara H, Nouso K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K, Toshimori J, Miyatake H, Ohnishi H, Shiraha H, Yamamoto K. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 2011;16:210-20. [DOI: 10.1007/s10147-010-0150-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
121 Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: A randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010;116:5452-60. [DOI: 10.1002/cncr.25314] [Cited by in Crossref: 187] [Cited by in F6Publishing: 175] [Article Influence: 15.6] [Reference Citation Analysis]
122 Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J. Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments. Aliment Pharmacol Ther 2018;48:664-70. [DOI: 10.1111/apt.14914] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
123 Tanaka H, Iijima H, Higashiura A, Yoh K, Ishii A, Takashima T, Sakai Y, Aizawa N, Iwata K, Ikeda N, Iwata Y, Enomoto H, Saito M, Imanishi H, Hirota S, Fujimoto J, Nishiguchi S. New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography. J Gastroenterol 2014;49:755-63. [DOI: 10.1007/s00535-013-0830-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
124 Shinkawa H, Hasegawa K, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, Kokudo N. Impact of Sustained Virological Response to Interferon Therapy on Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:3196-202. [DOI: 10.1245/s10434-017-6008-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
125 Okamoto M, Utsunomiya T, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, Hanai T, Inoue H, Mori M. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol. 2006;13:947-954. [PMID: 16788756 DOI: 10.1245/aso.2006.07.018] [Cited by in Crossref: 57] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
126 Nanashima A, Tobinaga S, Kunizaki M, Miuma S, Taura N, Takeshita H, Hidaka S, Sawai T, Nakao K, Nagayasu T. Strategy of treatment for hepatocellular carcinomas with vascular infiltration in patients undergoing hepatectomy. J Surg Oncol 2010;101:557-63. [PMID: 20213729 DOI: 10.1002/jso.21534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
127 Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy: NAGAOKI et al.. J Med Virol 2019;91:650-8. [DOI: 10.1002/jmv.25352] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
128 Li M, Wang Z, Cao J, Han B, Zou H, Zang Y, Wu L. Risk factors and prognosis of patients with recurrent hepatocellular carcinoma who undergo liver re-resections. European Journal of Surgical Oncology 2019;45:1684-90. [DOI: 10.1016/j.ejso.2019.04.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
129 Sun GP, Wang H, Xu SP, Shen YX, Wu Q, Chen ZD, Wei W. Anti-tumor effects of paeonol in a HepA-hepatoma bearing mouse model via induction of tumor cell apoptosis and stimulation of IL-2 and TNF-alpha production. Eur J Pharmacol 2008;584:246-52. [PMID: 18329639 DOI: 10.1016/j.ejphar.2008.02.016] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
130 Kaibori M, Matsui Y, Hijikawa T, Uchida Y, Kwon AH, Kamiyama Y. Comparison of limited and anatomic hepatic resection for hepatocellular carcinoma with hepatitis C. Surgery. 2006;139:385-394. [PMID: 16546504 DOI: 10.1016/j.surg.2005.08.035] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 5.1] [Reference Citation Analysis]
131 Tsao JI, DeSanctis J, Rossi RL, Oberfield RA. Hepatic malignancies. Surg Clin North Am. 2000;80:603-632. [PMID: 10836009 DOI: 10.1016/s0039-6109(05)70203-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
132 Qu LS, Zhang HF. Significance of viral status on prognosis of hepatitis B-related hepatocellular carcinoma after curative resection in East Asia. Hepatol Res 2016;46:40-9. [PMID: 25858122 DOI: 10.1111/hepr.12523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
133 Ueno S, Tanabe G, Yoshida A, Yoshidome S, Takao S, Aikou T. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer 1999;86:248-54. [DOI: 10.1002/(sici)1097-0142(19990715)86:2<248::aid-cncr8>3.0.co;2-1] [Cited by in Crossref: 23] [Article Influence: 1.0] [Reference Citation Analysis]
134 Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 2008;1299-1305. [PMID: 18515282 DOI: 10.1093/carcin/bgn113] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 7.5] [Reference Citation Analysis]
135 Sugimoto K, Shiraishi J, Tanaka H, Tsuchiya K, Aso K, Kobayashi Y, Iijima H, Moriyasu F. Computer-aided diagnosis for estimating the malignancy grade of hepatocellular carcinoma using contrast-enhanced ultrasound: an ROC observer study. Liver Int 2016;36:1026-32. [DOI: 10.1111/liv.13043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
136 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 183] [Article Influence: 15.2] [Reference Citation Analysis]
137 Poon RT, Fan S, Ng IO, Lo C, Liu C, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-7. [DOI: 10.1002/1097-0142(20000801)89:3<500::aid-cncr4>3.0.co;2-o] [Cited by in Crossref: 476] [Article Influence: 21.6] [Reference Citation Analysis]
138 Lee D, Chung YH, Kim JA, Park WH, Jin YJ, Shim JH, Ryu SH, Jang MK, Yu E, Lee YJ. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. Cancer. 2013;119:2239-2246. [PMID: 23564564 DOI: 10.1002/cncr.28082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
139 Li Q, Li H, Qin Y, Wang PP, Hao X. Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience. J Gastroenterol Hepatol. 2007;22:1936-1941. [PMID: 17914973 DOI: 10.1111/j.1440-1746.2006.04619.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
140 Zhang X, Li C, Wen T, Yan L, Li B, Yang J, Wang W, Xu M, Lu W, Jiang L. Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern. Eur J Gastroenterol Hepatol 2015;27:933-40. [PMID: 25933127 DOI: 10.1097/MEG.0000000000000383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
141 Okusaka T, Ueno H, Ikeda M, Mitsunaga S, Ozaka M, Ishii H, Yokosuka O, Ooka Y, Yoshimoto R, Yanagihara Y, Okita K. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol Res 2015;45:1283-91. [PMID: 25676869 DOI: 10.1111/hepr.12504] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
142 Shinkawa H, Uenishi T, Takemura S, Ohba K, Ogawa M, Ichikawa T, Kodai S, Yamamoto T, Tanaka H, Kubo S. Risk factors for postoperative recurrence of non-B non-C hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences 2010;17:291-5. [DOI: 10.1007/s00534-009-0186-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
143 Huang ZY, Liang BY, Xiong M, Zhan DQ, Wei S, Wang GP, Chen YF, Chen XP. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol 2012;19:2515-25. [PMID: 22395985 DOI: 10.1245/s10434-012-2269-7] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 7.0] [Reference Citation Analysis]
144 Gouillat C, Manganas D, Saguier G, Duque-campos R, Berard P. Resection of hepatocellular carcinoma in cirrhotic patients: longterm results of a prospective study11No competing interests declared. Journal of the American College of Surgeons 1999;189:282-90. [DOI: 10.1016/s1072-7515(99)00142-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
145 Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, Boeker K, Nashan B, Kubicka S, Maschek H, Tusch G, Raab R, Ringe B, Manns MP, Pichlmayr R. Recurrence Patterns of Hepatocellular and Fibrolamellar Carcinoma After Liver Transplantation. JCO 1999;17:324-324. [DOI: 10.1200/jco.1999.17.1.324] [Cited by in Crossref: 162] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
146 Hasegawa S, Yamasaki N, Hiwaki T, Sako K, Komorizono Y, Baba Y, Imamura Y, Kubozono O, Yoshida A, Arima T. Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. Cancer 1999;86:1682-90. [DOI: 10.1002/(sici)1097-0142(19991101)86:9<1682::aid-cncr9>3.0.co;2-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
147 Ng IO, Poon RT, Shek TW, Fan ST. Clinicopathologic and Prognostic Significance of the Histologic Activity of Noncancerous Liver Tissue in Hepatitis B Virus–Associated Hepatocellular Carcinoma. Am J Clin Pathol 2002;117:411-8. [DOI: 10.1309/4231-rcvb-wk8x-r1jk] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
148 Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2006;60:89-98. [DOI: 10.1016/j.critrevonc.2006.06.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 6.5] [Reference Citation Analysis]
149 Takai S, Matsushima-Nishiwaki R, Tokuda H, Yasuda E, Toyoda H, Kaneoka Y, Yamaguchi A, Kumada T, Kozawa O. Protein kinase C delta regulates the phosphorylation of heat shock protein 27 in human hepatocellular carcinoma. Life Sci. 2007;81:585-591. [PMID: 17673262 DOI: 10.1016/j.lfs.2007.06.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
150 Pichlmayr R, Weimann A, Oldhafer KJ, Schlitt HJ, Tusch G, Raab R. Appraisal of transplantation for malignant tumours of the liver with special reference to early stage hepatocellular carcinoma. Eur J Surg Oncol. 1998;24:60-67. [PMID: 9542520 DOI: 10.1016/s0748-7983(98)80130-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
151 Choi S, Park S, Cho YA, Park CK, Ha SY. Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma. Pathol Oncol Res 2020;26:2587-95. [PMID: 32623639 DOI: 10.1007/s12253-020-00871-7] [Reference Citation Analysis]
152 Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007; 13(39): 5188-5195 [PMID: 17876889 DOI: 10.3748/wjg.v13.i39.5188] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
153 Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y, Hino O. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology. 1999;29:1446-1452. [PMID: 10216128 DOI: 10.1002/hep.510290523] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 2.5] [Reference Citation Analysis]
154 Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, Blanc J, Sturm N, Bioulac-sage P, Nahon P, Nault J, Charnaux N, N’kontchou G, Trinchet J, Delehedde M, Seror O, Beaugrand M, Vicaut E, Ganne-carrié N. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. Journal of Hepatology 2013;59:1264-70. [DOI: 10.1016/j.jhep.2013.07.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
155 Ha SY, Song DH, Hwang SH, Cho SY, Park CK. Expression of prothymosin alpha predicts early recurrence and poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2015;14:171-7. [PMID: 25865690 DOI: 10.1016/s1499-3872(14)60326-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
156 Morita K, Shirabe K, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Ikegami T, Yamashita Y, Sugimachi K, Harimoto N, Itoh S, Ikeda T, Maehara Y. Relevance of microRNA-18a and microRNA-199a-5p to hepatocellular carcinoma recurrence after living donor liver transplantation: MIR-18A and MIR-199A-5P in HCC Recurrence. Liver Transpl 2016;22:665-76. [DOI: 10.1002/lt.24400] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
157 Miyagi T, Takehara T, Tatsumi T, Kanto T, Suzuki T, Jinushi M, Sugimoto Y, Sasaki Y, Hori M, Hayashi N. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer. 2003;106:81-89. [PMID: 12794761 DOI: 10.1002/ijc.11163] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 2.8] [Reference Citation Analysis]
158 Kuo KK, Jian SF, Li YJ, Wan SW, Weng CC, Fang K, Wu DC, Cheng KH. Epigenetic inactivation of transforming growth factor-β1 target gene HEYL, a novel tumor suppressor, is involved in the P53-induced apoptotic pathway in hepatocellular carcinoma. Hepatol Res 2015;45:782-93. [PMID: 25179429 DOI: 10.1111/hepr.12414] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
159 Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95:1931-1937. [PMID: 12404287 DOI: 10.1002/cncr.10892] [Cited by in Crossref: 145] [Cited by in F6Publishing: 141] [Article Influence: 7.3] [Reference Citation Analysis]
160 Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Kurokawa T, Nakamura N, Inazawa J, Tanaka H, Arii S. Surgical contribution to recurrence-free survival in patients with macrovascular-invasion-negative hepatocellular carcinoma. J Am Coll Surg 2009;208:368-74. [PMID: 19317998 DOI: 10.1016/j.jamcollsurg.2008.10.031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
161 Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, Kokubu S, Saigenji K. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol. 2008;43:71-78. [PMID: 18297439 DOI: 10.1007/s00535-007-2123-z] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 3.9] [Reference Citation Analysis]
162 Yue W, Wang S, Xu H, Sun L, Guo L, Bo X, Li X, Zhao C, Wang D, Liu B. Parametric imaging with contrast-enhanced ultrasound for differentiating hepatocellular carcinoma from metastatic liver cancer. CH 2016;64:177-88. [DOI: 10.3233/ch-162060] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
163 Rust C, Gores GJ. Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. Clin Liver Dis. 2001;5:161-173. [PMID: 11218913 DOI: 10.1016/s1089-3261(05)70159-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
164 Okuno M, Kojima S, Moriwaki H. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J Gastroenterol Hepatol. 2001;16:1329-1335. [PMID: 11851828 DOI: 10.1046/j.1440-1746.2001.02634.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
165 Tsujiuchi T, Sasaki Y, Kubozoe T, Tsutsumi M, Konishi Y, Nakae D. Alterations of the Fhit gene in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Mol Carcinog 2002;34:19-24. [PMID: 12112319 DOI: 10.1002/mc.10044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
166 Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H, Miyamoto A, Kondo M, Arai I, Yamamoto T, Ota H, Dono K, Umeshita K, Nakamori S, Sasaki Y, Ishikawa O, Imaoka S, Monden M. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol. 2003;39:215-221. [PMID: 12873818 DOI: 10.1016/s0168-8278(03)00233-2] [Cited by in Crossref: 83] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
167 Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, Kawabe T, Kawazoe S, Kobashi H, Kasugai H, Osaki Y, Araki Y, Izumi N, Oka H, Tsuji K, Toyota J, Seki T, Osawa T, Masaki N, Ichinose M, Seike M, Ishikawa A, Ueno Y, Tagawa K, Kuromatsu R, Sakisaka S, Ikeda H, Kuroda H, Kokuryu H, Yamashita T, Sakaida I, Katamoto T, Kikuchi K, Nomoto M, Omata M. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology. 2011;54:532-540. [PMID: 21574174 DOI: 10.1002/hep.24430] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 5.8] [Reference Citation Analysis]
168 Toyoda H, Kumada T, Kaneoka Y, Maeda A. Amino Acid Substitutions in the Hepatitis C Virus Core Region Are Associated With Postoperative Recurrence and Survival of Patients With HCV Genotype 1b-Associated Hepatocellular Carcinoma. Annals of Surgery 2011;254:326-32. [DOI: 10.1097/sla.0b013e3182263b8e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
169 Yasen M, Mizushima H, Mogushi K, Obulhasim G, Miyaguchi K, Inoue K, Nakahara I, Ohta T, Aihara A, Tanaka S. Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue. Cancer Sci. 2009;100:472-480. [PMID: 19134008 DOI: 10.1111/j.1349-7006.2008.01068.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
170 Santambrogio R, Opocher E, Zuin M, Selmi C, Bertolini E, Costa M, Conti M, Montorsi M. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class a liver cirrhosis. Ann Surg Oncol. 2009;16:3289-3298. [PMID: 19727960 DOI: 10.1245/s10434-009-0678-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
171 Yamamoto M, Takasaki K, Otsubo T, Saito A, Nakano M. Extent of resection for hepatocellular carcinoma 2 cm or less in greatest diameter. The American Journal of Surgery 2002;184:437-40. [DOI: 10.1016/s0002-9610(02)01005-x] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
172 Kamiyama T, Takahashi M, Nakanishi K, Yokoo H, Kamachi H, Kobayashi N, Ozaki M, Todo S. α-fetoprotein, vascular endothelial growth factor receptor-1 and early recurrence of hepatoma. World J Gastroenterol 2012; 18(4): 340-348 [PMID: 22294840 DOI: 10.3748/wjg.v18.i4.340] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
173 Wakai T, Shirai Y, Yokoyama N, Nagakura S, Hatakeyama K. Hepatitis viral status affects the pattern of intrahepatic recurrence after resection for hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 2003;29:266-71. [DOI: 10.1053/ejso.2002.1395] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
174 Kaneda K, Uenishi T, Takemura S, Shinkawa H, Urata Y, Sakae M, Yamamoto T, Kubo S. The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virus-related hepatocellular carcinoma: Influence of Diabetes on HCV-Related HCC. J Surg Oncol 2012;105:606-11. [DOI: 10.1002/jso.22137] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
175 Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol. 2009;5:889-899. [PMID: 19663737 DOI: 10.2217/fon.09.64] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
176 Choi JG, Chung YH, Kim JA, Jin YJ, Park WH, Lee D, Shim JH, Lee YS, Seo DD, Jang MK, Kim KM, Lim YS, Lee HC, Lee YS, Yu E, Lee YJ. High HBV-DNA titer in surrounding liver rather than in hepatocellular carcinoma tissue predisposes to recurrence after curative surgical resection. J Clin Gastroenterol 2012;46:413-9. [PMID: 22105184 DOI: 10.1097/MCG.0b013e3182371285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
177 Nagano Y, Shimada H, Ueda M, Matsuo K, Tanaka K, Endo I, Kunisaki C, Togo S. Efficacy of repeat hepatic resection for recurrent hepatocellular carcinomas. ANZ Journal of Surgery 2009;79:729-33. [DOI: 10.1111/j.1445-2197.2009.05059.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
178 Yoo J, Lee MW, Lee DH, Lee JH, Han JK. Evaluation of a serum tumour marker-based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma. Liver Int 2020;40:1189-200. [PMID: 32056353 DOI: 10.1111/liv.14406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
179 Ibrahim S, Roychowdhury A, Hean TK. Risk factors for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Am J Surg. 2007;194:17-22. [PMID: 17560903 DOI: 10.1016/j.amjsurg.2006.06.051] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
180 Ryu SH, Chung YH, Lee H, Kim JA, Shin HD, Min HJ, Seo DD, Jang MK, Yu E, Kim KW. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology. 2008;47:929-936. [PMID: 18306220 DOI: 10.1002/hep.22124] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 4.5] [Reference Citation Analysis]
181 Chang H, Yi B, Li L, Zhang HY, Sun F, Dong SQ, Cao Y. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients. Exp Mol Pathol. 2008;85:96-100. [PMID: 18691570 DOI: 10.1016/j.yexmp.2008.07.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
182 Min JH, Kang TW, Cha DI, Song KD, Lee MW, Rhim H, Sinn DH, Kim JM, Sohn I. Radiofrequency ablation versus surgical resection for multiple HCCs meeting the Milan criteria: propensity score analyses of 10-year therapeutic outcomes. Clin Radiol 2018;73:676.e15-24. [PMID: 29709236 DOI: 10.1016/j.crad.2018.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
183 Chen YJ, Yeh SH, Chen JT, Wu CC, Hsu MT, Tsai SF, Chen PJ, Lin CH. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000;119:431-40. [PMID: 10930378 DOI: 10.1053/gast.2000.9373] [Cited by in Crossref: 144] [Cited by in F6Publishing: 150] [Article Influence: 6.5] [Reference Citation Analysis]
184 Okamura Y, Ito T, Sugiura T, Mori K, Uesaka K. Anatomic versus nonanatomic hepatectomy for a solitary hepatocellular carcinoma : a case-controlled study with propensity score matching. J Gastrointest Surg 2014;18:1994-2002. [PMID: 25213582 DOI: 10.1007/s11605-014-2646-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
185 Toyoda H, Kumada T, Tada T, Sone Y, Fujimori M. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol 2012;23:317-22.e1. [PMID: 22265248 DOI: 10.1016/j.jvir.2011.11.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]